Table 5.
Proteus spp. susceptibility and resistance patterns.
| Tested Antibiotics | 2018 | 2020 | 2022 | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | R | NA | S | R | NA | S | R | NA | S | R | NA | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Amikacin | 30 (88.23) | 4 (11.76) | - | 23 (88.46) | 1 (3.84) | 2 (7.69) | 21 (100.0) | - | - | 74 (91.35) | 5 (6.17) | 2 (2.46) |
| Amoxicillin— Clavulanic ac. |
20 (58.82) | 11 (32.35) | 3 (8.82%) | 11 (24.3) | 8 (30.76) | 7 (26.92) | 15 (71.42) | 6 (28.57) | - | 46 (56.79) | 25 (30.86) | 10 (12.34) |
| Ceftazidime | 29 (85.29) | 5 (14.7) | - | 25 (96.15) | 1 (3.84) | - | 20 (95.43) | 1 (4.76) | - | 74 (91.35) | 7 (8.64) | - |
| Imipenem | 33 (97.05) | - | 1 (2.94%) | 20 (76.92) | 4 (15.38) | 2 (7.69) | 19 (90.47) | - | 2 (9.52) | 72 (88.88) | 4 (4.93) | 5 (6.17) |
| Levofloxacin | 21 (61.76) | 11 (32.35) | 2 (5.88%) | 17 (65.38) | 9 (34.61) | - | 11 (52.38) | 10 (47.61) | - | 49 (60.49) | 30 (37.03) | 2 (2.46) |
| Meropenem | 31 (91.17) | 1 (2.94) | 2 (5.88) | 24 (92.3) | 1 (3.84) | 1 (3.84) | 16 (76.19) | - | 5 (23.8) | 71 (87.65) | 2 (2.46) | 8 (9.87) |
n—number; %—percentage; R—resistance; S—susceptibility; NA—not available.